TGTX stock has been crushing the market this year with its shares surging high following the news that TG Therapeutics’ (NASDAQ:TGTX) refractory and relapsed MZL drug candidate umbralisib has been granted orphan drug designation by the FDA.
Umbralisib Achieved Primary EndpointEarly this year TG Therapeutics released mid-stage trial results for MZL, which showed that the drug achieved its primary endpoint of overall response rate. Following the positive results, umbralisib was granted Breakthrough Therapy Designation by the FDA for MZL which is good news for TGTX stock.
It is tricky to predict the near-term ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.